Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
April 8, 2025

ALX Oncology’s ALX2004 gains FDA IND clearance to treat solid tumours

ALX Oncology has received investigational new drug (IND) application clearance from the US Food and Drug Administration (FDA) for ALX2004, a new antibody-drug conjugate (ADC) aimed at treating solid tumours that express the epidermal growth factor receptor (EGFR).

Continue
Initial safety data from the trials are expected in the first half of 2026. Credit: Julia Koblitz on Unsplash.
April 7, 2025

FDA grants breakthrough therapy status for Amgen’s Uplizna to treat IgG4-RD

The trial was structured to assess the antibody against a placebo in minimising the flare risk in individuals with IgG4-RD. Credit: Diane Serik on Unsplash.
April 4, 2025

FDA clears Epicrispr’s application for FSHD treatment

Plans are underway to commence the global Phase I/II trial this year. Credit: Lucas Vasques on Unsplash.

Contracts

January 23, 2025

Kamada to supply immune globulin products in Latin America

KAMRAB must be administered alongside a complete rabies vaccine regimen. Credit: Nappy on Unsplash.

Bavarian Nordic secures $156.8m US vaccine deal

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Deals

Deals January 20, 2025

Fermion and Simcere to partner on development of pain treatment drug

Pharmaceutical Business Review

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Popular

  1. FDA grants fast track status to Biogen’s BIIB080 for Alzheimer’s
  2. EC grants orphan designation for Pharvaris’ deucrictibant drug
  3. Japan’s MHLW authorises Regeneron and Sanofi’s Dupixent for COPD
  4. BridgeBio’s Beyonttra gains approval in Japan for ATTR-CM treatment
  5. US FDA approves Exelixis’ Cabometyx for advanced neuroendocrine tumours

PRESS RELEASES

LTS Wins Funding from BARDA’s Patch Forward Prize Competition for Two artnerships
LTS Wins Funding from BARDA’s Patch Forward Prize Competition for Two artnerships
Gerresheimer Delivers Solid Results in the Financial Year 2024 Despite Market Headwinds
Gerresheimer Delivers Solid Results in the Financial Year 2024 Despite Market Headwinds
Two Stories, One Future: Gerresheimer and Bormioli Pharma at Pharmapack 2025
Two Stories, One Future: Gerresheimer and Bormioli Pharma at Pharmapack 2025
Gerresheimer Successfully Completes Acquisition of Blitz LuxCo, the Holding Company of the Bormioli Pharma Group
Gerresheimer Successfully Completes Acquisition of Blitz LuxCo, the Holding Company of the Bormioli Pharma Group
Gerresheimer Builds New Production Capacities for Glass Syringes at Skopje Site
Gerresheimer Builds New Production Capacities for Glass Syringes at Skopje Site

Suppliers

Whitepapers

Saving Through Partnership and Innovation
Saving Through Partnership and Innovation
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Wound Care – Selecting the Right Antiseptic for Your Formulation
Wound Care – Selecting the Right Antiseptic for Your Formulation